Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by Thomas Jefferson University
Sponsor:
Information provided by (Responsible Party):
Thomas Jefferson University
ClinicalTrials.gov Identifier:
NCT01514565
First received: January 17, 2012
Last updated: February 4, 2014
Last verified: February 2014

January 17, 2012
February 4, 2014
December 2011
December 2014   (final data collection date for primary outcome measure)
Histological status of retinoblastoma tumour suppressor (RB) [ Time Frame: Nine weeks ] [ Designated as safety issue: No ]
The primary endpoint is to assess the impact of histological RB-status on pathological complete response (pCR). pCR is a well validated surrogate of chemotherapy sensitivity and allows the identification of a group of patients with excellent prognosis.
Same as current
Complete list of historical versions of study NCT01514565 on ClinicalTrials.gov Archive Site
  • Correlation of RB and other biomarkers [ Time Frame: Nine weeks ] [ Designated as safety issue: No ]
    1. Correlation between RB and PTEN tumor suppressor status and other biomarkers with pCR
    2. Correlation between RB-status, RB and PTEN status and other biomarkers with recurrence free survival (RFS) and overall survival (OS)
  • Determine the utility of an RB molecular test [ Time Frame: Assessed within 1 year ] [ Designated as safety issue: No ]
    Gene expression profiling of biopsy specimens to determine utility of an RB molecular test.
Same as current
Not Provided
Not Provided
 
Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer
Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer.

This is a prospective observational study aimed to validate biomarkers that predict response.

This is a prospective observational cohort study, with no control group and no direct experimental intervention, where the patient's pathological material will be used to examine the expression of molecular biomarkers believed to predict chemotherapy response. Patients with locally advanced triple negative breast cancer, who are candidates for neoadjuvant chemotherapy, will be enrolled in this clinical study. Patients will receive standard of care, FDA-approved and clinically validated chemotherapy regimens. The biopsy specimens taken during the diagnostic phase (pre-treatment specimen) will be used for specific biomarker evaluation. Data obtained from this pre-treatment phase will be compared with the surgical specimens (post-treatment phase) obtained after receiving neoadjuvant chemotherapy. The primary endpoint is to assess the ability of specific biomarkers to predict treatment response, and thus identify those patients who will achieve benefit from such treatment.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

A maximum of 70 eligible patients will be enrolled. Accrual is expected to be completed in 18-24 months. All patients must have histologically confirmed triple negative breast cancer and be eligible to receive neoadjuvant chemotherapy.

Breast Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
70
December 2018
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age > 18 years old
  • Histologically-confirmed triple negative invasive breast carcinoma
  • Any type of ductal or lobular invasive carcinoma
  • Patients with or without BRCA-1 and BRCA-2 mutations are eligible to participate
  • Life expectancy > 6 months
  • Pre-, Peri- or Postmenopausal
  • Clinical Stage T2-4, N0-3, M0 (Stage II-III)
  • Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial
  • Adequate hematologic, renal, and liver function and functional status that permit chemotherapy administration. However, these parameters will be evaluated by the treating physician, and decisions regarding eligibility for chemotherapy or surgery will be made on a case by case scenario.

Exclusion Criteria:

  • Prior history of and/or active therapy for invasive breast cancer (includes chemotherapy, radiation, hormonal therapy including AIs, tamoxifen, raloxifene, fulvestrant or any other antiestrogen/SERM)
  • Patients with a "currently active" second malignancy other than non-melanoma skin cancers are not to be registered. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are now considered to be at less than 30% risk for relapse (by their physician).
  • Only ductal/lobular carcinoma in situ but not invasive component
  • Any sort of confirmed metastatic disease (AJCC Stage IV at diagnosis)
  • Any sort of active local radiation therapy (to the breast or the axilla), before the neoadjuvant chemotherapy
  • Pregnant or lactating, in case this precludes the subject to receive chemotherapy.
  • Impossibility to receive neoadjuvant chemotherapy due to significant medical comorbidities, allergies or performance status. This will be exclusively decided by the treating oncologists.
Female
18 Years and older
No
Contact: Agnieszka Witkiewicz, MD 215-955-3778 Agnieszka.Witkiewicz@jefferson.edu
Contact: Gordon Schwartz, MD 215-955-6999 Gordon.Schwartz@jefferson.edu
United States
 
NCT01514565
11D-574
No
Thomas Jefferson University
Thomas Jefferson University
Not Provided
Principal Investigator: Agnieszka Witkiewicz, MD Thomas Jefferson University
Principal Investigator: Gordon Schwartz, MD Thomas Jefferson University
Thomas Jefferson University
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP